Also, new (immuno)therapy options for advanced NSCLC patients will emerge, such as combined CTLA4 and PD1 checkpoint blockers, and predictive biomarkers can be useful in deciding which patients should receive these new alternatives and for which patients the current immunotherapy is likely to suffice. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.